UK markets closed

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
129.69+2.24 (+1.75%)
As of 12:13PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close127.45
Open131.65
Bid0.00 x 0
Ask0.00 x 0
Day's range124.50 - 131.65
52-week range74.70 - 140.32
Volume2,021
Avg. volume43,059
Market cap581.011B
Beta (5Y monthly)0.17
PE ratio (TTM)48.03
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.86 (1.46%)
Ex-dividend date22 Mar 2024
1y target estN/A
  • Globe Newswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 25 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the programme i

  • Globe Newswire

    Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

    Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets

  • Globe Newswire

    Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities

    Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli® (the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults. The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme. Once-weekly basal insulin icodec achieved superior blood sugar reduction1 (